 Moderna Therapeutics Inc NASDAQ:MRNA shares rallied after the biotechnology firm told investors that a trial that combined its investigational cancer vaccine with drug giant Merck Co Inc NYSE:MRKs immunotherapy Keytruda for patients with stage IIIIV melanoma reduced the risk of recurrence or death by 44. Moderna said the Phase 2b trial of its mRNA cancer vaccine in combination with Keytruda demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival versus Keytruda alone. 